Major interaction on record — check this product against your medications before combining. Based on 16 of 24 ingredients. Check your meds →

Dietary supplement

All Plant Protein Powder Ingredients & Drug Interactions

Q: Does All Plant Protein Powder by Nutrilite interact with any medications?

Yes. Based on its ingredients, All Plant Protein Powder has a known interaction with 1,138 medications, including 263 rated major. Use the checker to see how it interacts with a specific drug.

Q: How can one product interact with so many drugs?

All Plant Protein Powder contains 24 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.

Q: Where does this information come from?

The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.

Q: Can I take this if I'm on blood pressure medication?

Not without checking first. The sodium in this product can reduce how well blood pressure drugs work, and the potassium can interact with certain blood pressure meds like ACE inhibitors or ARBs. Your pharmacist can tell you whether your specific medication is affected.

Q: Is this safe during pregnancy?

Some ingredients are fine in pregnancy — calcium, potassium, and iron at recommended amounts are likely safe. But phenylalanine is unsafe at supplemental doses in pregnancy, and aspartic acid, tryptophan, and serine don't have enough data. Talk with your doctor or pharmacist before starting, especially since this is a multi-ingredient product.

Q: Will this help me build muscle?

The data we hold don't establish that the amino acids in this product are effective for muscle strength or athletic performance. It's a protein source, and protein does support muscle — but whether this specific blend is better than other protein powders, the evidence doesn't say.

Q: What does L-tryptophan in this product do?

L-tryptophan is an amino acid your body uses to make serotonin, which affects mood and sleep. The evidence suggests it may not be effective for depression. It can cause drowsiness, and it interacts with antidepressants and sedatives, so mention it to your pharmacist if you take those.

Q: Can I take this with my thyroid medication?

Iron in this powder can reduce how well levothyroxine (Synthroid) is absorbed. If you take thyroid medication, separate your doses by at least 2 hours — take one in the morning and the other much later — and ask your pharmacist to monitor whether your dosage needs adjusting.

Q: Does this product have fillers?

Yes. In addition to the active amino acids and minerals, it contains soy protein isolate, wheat protein, pea protein, lecithin, and silicon dioxide, which are inactive ingredients that help make the powder work as a product.

by Nutrilite

See full label image

Powder Category: Amino Acid/protein

Most serious interaction: Major

Clinical methodology reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Sep 9, 2026 · Label data from the NIH DSLD

What is this page for?

First and foremost: checking All Plant Protein Powder against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Major

All Plant Protein Powder is a dietary supplement by Nutrilite with 24 active ingredients. Its ingredients are commonly taken for replacing fluids and electrolytes, preventing dehydration during exercise or illness, treating low blood sodium (under medical care).Based on those ingredients, 1,138 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Vitamin D, Tryptophan, Sodium. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against All Plant Protein Powder by Nutrilite

Ask about any prescription or over-the-counter medication and we check it for interactions with All Plant Protein Powder by Nutrilite — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds

AI summaries are generated from our interaction database for education only — always confirm with your pharmacist. How we use AI

Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of All Plant Protein Powder by Nutrilite

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Jul 12, 2026

What’s inside

Partial disclosure

Ingredient Transparency · database check

Partial

Most active ingredients list an amount, but at least one is hidden in a blend or missing.

Why this rating?

The label discloses an exact amount for 21 of its 23 active ingredients.
“One serving provides the following Typical Amino Acids” is listed as a grouped ingredient — the label doesn't break down how much of each component you get.

Nutrilite All Plant Protein Powder contains 23 active ingredients, primarily amino acids and minerals that support protein function and general nutrition. The amino acids include glycine, aspartic acid, L-tryptophan, cysteine, methionine, arginine, leucine, serine, tyrosine, histidine, isoleucine, lysine, phenylalanine, threonine, valine, glutamic acid, alanine, and proline.

The product also provides sodium, potassium, calcium, iron, and vitamin D. The powder includes inactive ingredients — soy protein isolate, wheat protein, pea protein, lecithin, and silicon dioxide — which serve as the base and binding agents.

Does it work?

Strong evidence

Evidence for Intended Use · database check

By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed

This product doesn't appear to be marketed for a specific use, so we graded its ingredients' overall clinical evidence instead.

Strong

Strong clinical evidence supports its ingredients for:

Anemia of chronic disease via Iron Effective
Dyspepsia via Calcium Effective
Hypocalcemia via Calcium Effective
Familial hypophosphatemia via Vitamin D Effective
Iron deficiency anemia via Iron Effective

Why this rating?

We looked at the product name, claims, and label statements and couldn't find a stated purpose to grade.
Since the label doesn't commit to one use, we graded the ingredients' overall clinical evidence instead.
On file: Anemia of chronic disease — rated "Effective" (Iron) (Natural Medicines).
On file: Dyspepsia — rated "Effective" (Calcium) (Natural Medicines).
On file: Hypocalcemia — rated "Effective" (Calcium) (Natural Medicines).
On file: Familial hypophosphatemia — rated "Effective" (Vitamin D) (Natural Medicines).
On file: Iron deficiency anemia — rated "Effective" (Iron) (Natural Medicines).

The evidence for this product's ingredients varies widely. Calcium is effective for kidney failure, dyspepsia, low blood calcium (hypocalcemia), and high blood potassium (hyperkalemia), and likely effective for osteoporosis.

Iron is effective for iron-deficiency anemia and anemia of chronic disease, and possibly effective for heart failure. Vitamin D is effective for several conditions including rickets, renal bone disease (osteodystrophy), and low blood calcium states.

Lysine is possibly effective for cold sores. Most of the amino acids — including aspartic acid, tryptophan, glycine, methionine, serine, and several others — lack enough evidence to rate their effectiveness for any condition, or the evidence suggests they're not effective.

If you're taking this product to address a specific health concern, we'd recommend talking with your pharmacist about whether the evidence supports it.

The evidence, ingredient by ingredient Sodium Potassium Calcium Iron Vitamin D Glycine Aspartic Acid L-tryptophan

How safe is it?

Well-documented data

Safety Information · database check

Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?

We hold adverse-effect (side-effect) data for 13 of the 16 matched ingredients.
Pregnancy & breastfeeding safety ratings cover 16 of 16.
General safety write-ups exist for 16 of 16.
Remember: this measures how much safety information exists. Thin data is not the same as being safe.

The active minerals in this product are generally well tolerated at recommended dietary amounts. Calcium, potassium, and vitamin D are common in food and safe at normal intake levels — though very high doses of vitamin D over time can cause toxicity with symptoms of high blood calcium (hypercalcemia).

Sodium should be kept within normal dietary limits; excessive sodium is linked to high blood pressure and heart strain, and people with kidney disease or heart conditions need to be careful. Iron can cause nausea, constipation, and diarrhea in some people, and supplements should be used only when there's a genuine need.

The amino acids are generally well tolerated; tryptophan has caused rare side effects including drowsiness and nausea, and it carries a historical concern from contaminated batches in the late 1980s. For pregnancy and breastfeeding, calcium, potassium, iron, and vitamin D are rated likely safe at recommended amounts; phenylalanine is unsafe in pregnancy at supplemental doses; aspartic acid, tryptophan, and serine are possibly unsafe in pregnancy; and several others lack enough data to know either way.

Side effects, ingredient by ingredient Sodium Potassium Calcium Iron Vitamin D Glycine Aspartic Acid L-tryptophan

Meds to double-check

Major interaction found

Known Interaction Concern · database check

Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?

11 of the 16 matched ingredients can interact with medications — Lysine, L-tryptophan, Phenylalanine, Calcium, Potassium, among others.
The most serious interaction on file is rated Major.
Some involve high-stakes drug classes: heart-rhythm medications; lithium; Parkinson's medications.
For scale: 1,139 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking Nutrilite All Plant Protein Powder, check with your pharmacist if you take any of these: blood pressure medications and drugs for hypertension (sodium and potassium can interfere), lithium, potassium-sparing diuretics, ACE inhibitors or ARBs, thyroid medication (levothyroxine), levodopa (for Parkinson disease), antibiotics including quinolones and tetracyclines, or heart rhythm medications like digoxin, verapamil, or diltiazem. CNS depressants (sedatives and sleep aids) and antidepressants also warrant a check due to interactions with tryptophan.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glancePartially disclosed formula with strong clinical evidence behind its ingredients' uses. Major medication interactions have been identified, and safety information is well characterized.

This is a plant-based protein powder with added vitamins and minerals. It's useful if you need a protein supplement and want a plant source.

However, if you take any blood pressure medications, lithium, heart rhythm drugs, thyroid medication, antibiotics, or medications for Parkinson disease, you need to check this product against your exact prescriptions first — interactions are possible. Talk with your pharmacist before starting, especially if you have kidney disease, heart disease, or are pregnant or breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 16 of 23 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jan 22, 2021.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about All Plant Protein Powder, straight from the product label.

Brand	Nutrilite
Barcode (UPC)	110415
Net contents	15.97 Oz(s); 450 Gram(s)
Market status	On market
Date entered into DSLD	Jan 22, 2021
DSLD ID	242685
Product type	Amino Acid/protein
Supplement form	Powder
Dietary claims / uses	Nutrient, All Other, Structure/Function
Intended target group(s)	Vegetarian, Adult (18 - 50 Years), Kosher, Halal

From the label

Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for All Plant Protein Powder by Nutrilite, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):

Adults and children 4 or more years of age

Minimum serving Sizes:

2 Tbsp

Maximum serving Sizes:

2 Tbsp

Servings per container

UPC/BARCODE

110415

Ingredient	Amount	% DV
Calories	50 Calorie(s)	--
Protein	10 Gram(s)	20%
Sodium	125 mg	5%
Potassium	0 mg	--
Cholesterol	0 mg	--
Calcium	25 mg	2%
Iron	1 mg	6%
Total Fat	0.5 Gram(s)	1%
Glycine	410 mg	--
Aspartic Acid	1100 mg	--
Tryptophan	150 mg	--
Vitamin D	0 mcg	--
Cysteine	280 mg	--
Methionine	280 mg	--
Arginine	750 mg	--
Leucine	830 mg	--
Serine	530 mg	--
Tyrosine	940 mg	--
Histidine	260 mg	--
Isoleucine	490 mg	--
Lysine	640 mg	--
Phenylalanine	940 mg	--
Threonine	390 mg	--
Valine	500 mg	--
Glutamic Acid	2100 mg	--
Alanine	430 mg	--
Proline	630 mg	--
One serving provides the following Typical Amino Acids	0 NP	--

Other ingredients: Soy Protein isolate, Wheat Protein, Pea Protein, Lecithin, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements

These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.

FDA Disclaimer Statement

This statement have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

General Statements

Exclusively from Amway

Quality you can trust Since 1934

Servings Per Container: 36 servings (based on average serving size of 12.5 grams)

A reasonable daily intake is two (2) servings.

Notice: This product was filled to capacity at the time of manufacture. However, the product tends to settle during shipment.

Brand IP Statement(s)

Formula

Star-K

Cresent M

A Blend of Soy, Wheat, and Pea Proteins High Quality, Complete Protein All Essential Amino Acids

Low Fat

It's your body - Protein fulfills a leading role in helping you maintain a lean body and build muscle mass while minimizing muscle fatigue and sustaining energy. Because your body does not store excess protein, daily intake is necessary to ensure that your body gets all the protein it needs. Nutrilite All Plant Protein Powder provides a 100% plant-based, cholesterol free protein. Complete Protein - Nutrilite All Plant Protein Powder provides high quality protein, supplying balanced amounts of the nine essential amino acids. All this and it is lactose free.

The smart choice - Nutrilite All Plant Protein Powder supports heart health by providing protein with no cholesterol. And, because Nutrilite All Plant Protein Powder promotes satiety, you are less likely to snack between meals because you will feel less hungry. Just one 12.5 g serving of Nutrilite All Plant Protein Powder provides 10 g of protein and is a low-fat alternative to traditional sources of protein such as red meats, cheeses, eggs and whole milk.

This product is more than 80% protein. Contains soy and wheat.

Seals/Symbols

Star-K Crescent M Contents Certified NSF

FDA Statement of Identity

Dietary Supplement

Formulation

Cholesterol free Lactose free Non-GMO Sources

Vegetarian

All this and it is lactose free.

Energy, Muscle, and Heart Health

Suggested/Recommended/Usage/Directions

How to prepare and use According to need, add contents of two level tablespoons (approximately 12.5 grams) to an 8 fl. oz. glass of milk, fruit juice, vegetable juice or other liquid once or several times per day. Sweeteners or flavors may be added, if desired. Stir rapidly for 45 seconds or shake vigorously in a covered container. NutriliteAll Plant Protein Powder can also be sprinkled on rice dishes, cereals, vegetables, salads or soups. In addition, it can be added to casseroles, breads, cakes, biscuit or meat recipes and many other foods. It increases the protein value and has a neutral taste.

Precautions

Contains soy and wheat.

Storage

Keep container tightly closed to protect from moisture. Store in a cool dry place below 74 degrees Fahrenheit.

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

All Plant Protein Powder by Nutrilite label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)

What’s inside

The Ingredients in All Plant Protein Powder by Nutrilite

These are the 24 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Tbsp Dosage formPowder Servings per container36 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Protein

10 Gram(s) per serving

Sodium

Interacts with
205 drugs

125 mg per serving

Sodium is an essential mineral and electrolyte your body needs to balance fluids, support nerves, and help muscles work. Most people in modern diets g...

Sodium monograph & interactions

Potassium

Interacts with
62 drugs

0 mg per serving

Potassium is an essential mineral your body needs for nerve signals, muscle function, and a steady heartbeat, and most people get enough from a balanc...

Potassium monograph & interactions

Calcium

Interacts with
168 drugs

25 mg per serving

Calcium is an essential mineral your body needs for strong bones, nerve signaling, and muscle function, and supplements can help fill gaps when diet f...

Calcium monograph & interactions

Iron

Interacts with
80 drugs

1 mg per serving

Iron is an essential mineral your body needs to make hemoglobin and carry oxygen in the blood. Supplements are mainly useful for treating or preventin...

Iron monograph & interactions

Vitamin D

Interacts with
715 drugs

0 mcg per serving

Vitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people,...

Vitamin D monograph & interactions

One serving provides the following Typical Amino Acids

0 NP per serving

› Glycine
› Aspartic Acid
› Tryptophan
› Cysteine
› Methionine
› Arginine
› Leucine
› Serine
› Tyrosine
› Histidine
› Isoleucine
› Lysine
› Phenylalanine
› Threonine
› Valine
› Glutamic Acid
› Alanine
› Proline

Other (inactive) ingredients: Soy Protein isolate, Wheat Protein, Pea Protein, Lecithin, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

HelloPharmacist.com · Pharmacist card

All Plant Protein Powder

by Nutrilite · label dated Jan 22, 2021

Scan for the full live report

Known drug interactions: 1,138 medications — most serious rated major

Active ingredients

Protein, Sodium, Potassium, Calcium, Iron, Vitamin D, One serving provides the following Typical Amino Acids

Most serious documented interactions

Acepromazine — Major (via Tryptophan)
Acetaminophen, Butalbital, Caffeine, Codeine — Major (via Tryptophan)
Acetaminophen, Butalbital, Codeine — Major (via Tryptophan)

Full interaction list, ingredient monographs & live checker: https://hellopharmacist.com/drug-supplement-interactions/supplements/all-plant-protein-powder-by-nutrilite-8106
Printed · Educational information only — not medical advice. Confirm against the physical product label and with your pharmacist.

Interaction report

All Plant Protein Powder by Nutrilite Drug Interactions

All Plant Protein Powder — Nutrilite · HelloPharmacist interaction report
Active ingredients: Protein, Sodium, Potassium, Calcium, Iron, Vitamin D, One serving provides the following Typical Amino Acids
Source label: Jan 22, 2021 · Printed · HelloPharmacist.com
Educational information only — not medical advice. Confirm against the physical product label and with your pharmacist.

HelloPharmacist Interaction Report

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Clinical methodology reviewed by Dr. Brian Staiger, PharmD, BCPS · Last generated Jul 12, 2026

24 active ingredients 11 with known interactions 1,138 medications covered

Nutrilite All Plant Protein Powder contains several active ingredients that interact with medications.

The most serious concern is calcium, which has Major-severity interactions with three HIV medications: dolutegravir and elvitegravir both require dosing separated by 2 hours or more, and ceftriaxone (an antibiotic) cannot be given intravenously within 48 hours of calcium.

Read the full breakdown — every affected drug type, severity by severity

Sodium in this product interacts with blood pressure medications, lithium, corticosteroids, and several other drug types at Moderate severity. High sodium intake can reduce how well blood pressure drugs work and can shift lithium levels dangerously.

Potassium poses Moderate-severity risks with ACE inhibitors, ARBs, and potassium-sparing diuretics — combining them raises the risk of dangerously high blood potassium levels (hyperkalemia).

Iron reduces absorption of antibiotics (quinolones and tetracyclines), thyroid medication (levothyroxine), and several other drugs — all Moderate severity. Phenylalanine has a Major interaction with levodopa (Parkinson medication), reducing its effectiveness.

L-tryptophan carries a Major interaction with CNS depressants (sedatives, sleep aids) and a Moderate interaction with serotonergic drugs like antidepressants.

Vitamin D, at high doses, interacts Moderately with heart rhythm medications (verapamil, diltiazem, digoxin), thiazide diuretics, and statin cholesterol drugs. Glycine, tyrosine, and threonine each carry one Moderate interaction.

Altogether, these interactions span 1,126 individual medications. Check your exact prescriptions using the tool below before starting this product.

Check your own medications below · Editorial policy · How we use AI

Want to check YOUR meds against All Plant Protein Powder?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker

1,138Drugs

263 Major 468 Moderate 407 Minor

Ingredients driving the most interactions

Vitamin D 715

Tryptophan 394

Sodium 205

Calcium 168

Iron 80

Individual Drug Interactions

The ingredients in All Plant Protein Powder interact with 1,138 drugs. Click any drug to see the details.

11 of the 24 ingredients in All Plant Protein Powder interact with drugs. Each result below shows which ingredient is responsible. Vitamin D Tryptophan Sodium Calcium Iron Potassium Tyrosine Phenylalanine Threonine Glycine Lysine

All interactions 1,138 Major 263 Moderate 468 Minor 407

Showing 1–30 of 1,138 drugs.

AcepromazineAtravet

Major

Acepromazine belongs to Cns Depressants — the drug category that interacts with this product

How Acepromazine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acepromazine interaction

Acetaminophen, Butalbital, Caffeine, CodeineEsgic with Codeine, Fioricet w/ Codeine

Major

Acetaminophen, Butalbital, Caffeine, Codeine belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Butalbital, Caffeine, Codeine interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Butalbital, Caffeine, Codeine interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Butalbital, Caffeine, Codeine interaction

Acetaminophen, Butalbital, CodeineBancap w/ Codeine

Major

Acetaminophen, Butalbital, Codeine belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Butalbital, Codeine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Butalbital, Codeine interaction

Acetaminophen, Butalbital, Codeine PhosphatePhrenilin #3

Major

Acetaminophen, Butalbital, Codeine Phosphate belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Butalbital, Codeine Phosphate interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Butalbital, Codeine Phosphate interaction

Acetaminophen, Caffeine, Chlorpheniramine, Hydrocodone, PhenylephrineHycomine Compound

Major

Acetaminophen, Caffeine, Chlorpheniramine, Hydrocodone, Phenylephrine belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Caffeine, Chlorpheniramine, Hydrocodone, Phenylephrine interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Caffeine, Chlorpheniramine, Hydrocodone, Phenylephrine interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Caffeine, Chlorpheniramine, Hydrocodone, Phenylephrine interaction

Acetaminophen, Caffeine, CodeineGesic C15, Gesic C30, Gesic C8, Lenoltec 1, Lenoltec 2, Lenoltec 3 +1 more

Major

Acetaminophen, Caffeine, Codeine belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Caffeine, Codeine interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Caffeine, Codeine interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Caffeine, Codeine interaction

Acetaminophen, Caffeine, Codeine, SalicylamideCodalan No.1, Codalan No.2, Codalan No.3

Major

Acetaminophen, Caffeine, Codeine, Salicylamide belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Caffeine, Codeine, Salicylamide interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Caffeine, Codeine, Salicylamide interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Caffeine, Codeine, Salicylamide interaction

Acetaminophen, Caffeine, DihydrocodeineDHC Plus, Panlor DC, Panlor SS

Major

Acetaminophen, Caffeine, Dihydrocodeine belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Caffeine, Dihydrocodeine interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Caffeine, Dihydrocodeine interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Caffeine, Dihydrocodeine interaction

Acetaminophen, Chlorpheniramine, Codeine, PhenylephrineColrex

Major

Acetaminophen, Chlorpheniramine, Codeine, Phenylephrine belongs to Serotonergic DrugsCns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Chlorpheniramine, Codeine, Phenylephrine interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanSerotonergic Drugs, Cns Depressants Major

Interaction Summary

Theoretically, combining L-tryptophan with serotonergic drugs might cause additive serotonergic effects.

Read the full Tryptophan + Acetaminophen, Chlorpheniramine, Codeine, Phenylephrine interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Chlorpheniramine, Codeine, Phenylephrine interaction

Acetaminophen, Chlorpheniramine, Phenylpropanolamine, OpiumHista-Derfule

Major

Acetaminophen, Chlorpheniramine, Phenylpropanolamine, Opium belongs to Serotonergic DrugsCns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Chlorpheniramine, Phenylpropanolamine, Opium interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanSerotonergic Drugs, Cns Depressants Major

Interaction Summary

Theoretically, combining L-tryptophan with serotonergic drugs might cause additive serotonergic effects.

Read the full Tryptophan + Acetaminophen, Chlorpheniramine, Phenylpropanolamine, Opium interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Chlorpheniramine, Phenylpropanolamine, Opium interaction

Acetaminophen, Chlorzoxazone, CodeineAcetazone Forte C8, Parafon Forte C8

Major

Acetaminophen, Chlorzoxazone, Codeine belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Chlorzoxazone, Codeine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Chlorzoxazone, Codeine interaction

Acetaminophen, CodeineTylenol No.3, Tylenol w/ Codeine

Major

Acetaminophen, Codeine belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Codeine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Codeine interaction

Acetaminophen, Codeine, DoxylamineMersyndol

Major

Acetaminophen, Codeine, Doxylamine belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Codeine, Doxylamine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Codeine, Doxylamine interaction

Acetaminophen, Codeine, MethocarbamolAcetaminophen, Codeine, Methocarbamol, Robaxacet 8

Major

Acetaminophen, Codeine, Methocarbamol belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Codeine, Methocarbamol interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Codeine, Methocarbamol interaction

Acetaminophen, Dichloralantipyrine, IsomethepteneAmidrine, Midchlor, Migquin, Migratine

Major

Acetaminophen, Dichloralantipyrine, Isometheptene belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Dichloralantipyrine, Isometheptene interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Dichloralantipyrine, Isometheptene interaction

Acetaminophen, Dichloralphenazone, IsomethepteneMidrin

Major

Acetaminophen, Dichloralphenazone, Isometheptene belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Dichloralphenazone, Isometheptene interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Dichloralphenazone, Isometheptene interaction

Acetaminophen, Dichlorophenazone, IsometheptaneIsocom

Major

Acetaminophen, Dichlorophenazone, Isometheptane belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Dichlorophenazone, Isometheptane interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Dichlorophenazone, Isometheptane interaction

Acetaminophen, DiphenhydramineTylenol PM, Tylenol PM Ex Strength

Major

Acetaminophen, Diphenhydramine belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Diphenhydramine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Diphenhydramine interaction

Acetaminophen, Diphenhydramine, PseudoephedrineChildren's Tylenol Allergy, Cold Control, Contac Night Allergy Relief

Major

Acetaminophen, Diphenhydramine, Pseudoephedrine belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Diphenhydramine, Pseudoephedrine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Diphenhydramine, Pseudoephedrine interaction

Acetaminophen, HydrocodoneAnexsia, Anodynos DHC, Azdone, Co-Gesic, Doucet, Lorcet +9 more

Major

Acetaminophen, Hydrocodone belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Acetaminophen, Hydrocodone interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Hydrocodone interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Acetaminophen, Hydrocodone interaction

Acetaminophen, MeperidineDemerol APAP

Major

Acetaminophen, Meperidine belongs to Cns DepressantsSerotonergic Drugs — the drug categories that interact with this product

How Acetaminophen, Meperidine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants, Serotonergic Drugs Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Meperidine interaction

Acetaminophen, OxycodonePercocet, Roxicet, Tylox, Xartemis XR

Major

Acetaminophen, Oxycodone belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Oxycodone interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Oxycodone interaction

Acetaminophen, PentazocineTalacen

Major

Acetaminophen, Pentazocine belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Pentazocine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Pentazocine interaction

Acetaminophen, PropoxypheneDarvocet-N 100, Darvocet-N 50, E-Lor, Wygesic

Major

Acetaminophen, Propoxyphene belongs to Cns Depressants — the drug category that interacts with this product

How Acetaminophen, Propoxyphene interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetaminophen, Propoxyphene interaction

AcetazolamideAk-Zol, Diamox

Major

Acetazolamide belongs to Cns DepressantsAntihypertensive Drugs — the drug categories that interact with this product

How Acetazolamide interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Acetazolamide interaction

SodiumAntihypertensive Drugs Moderate

Interaction Summary

Theoretically, a high intake of dietary sodium might reduce the effectiveness of antihypertensive drugs.

Read the full Sodium + Acetazolamide interaction

See the Acetazolamide drug page: uses, dosage & side effects

AlfentanilAlfenta

Major

Alfentanil belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Alfentanil interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Alfentanil interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Alfentanil interaction

AlprazolamNiravam, Xanax

Major

Alprazolam belongs to Cns DepressantsCytochrome P450 3a4 (cyp3a4) Substrates — the drug categories that interact with this product

How Alprazolam interacts with All Plant Protein Powder — through 2 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Alprazolam interaction

Vitamin DCytochrome P450 3a4 (cyp3a4) Substrates Minor

Interaction Summary

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.

Read the full Vitamin D + Alprazolam interaction

See the Alprazolam drug page: uses, dosage & side effects

Aluminum Hydroxide, Aspirin, Codeine Phosphate, Magnesium HydroxideAscriptin Codeine #2

Major

Aluminum Hydroxide, Aspirin, Codeine Phosphate, Magnesium Hydroxide belongs to Cns DepressantsAluminum — the drug categories that interact with this product

How Aluminum Hydroxide, Aspirin, Codeine Phosphate, Magnesium Hydroxide interacts with All Plant Protein Powder — through 3 ingredients. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Aluminum Hydroxide, Aspirin, Codeine Phosphate, Magnesium Hydroxide interaction

CalciumAluminum Moderate

Interaction Summary

Calcium citrate might increase aluminum absorption and toxicity.

Read the full Calcium + Aluminum Hydroxide, Aspirin, Codeine Phosphate, Magnesium Hydroxide interaction

Vitamin DAluminum Moderate

Interaction Summary

Vitamin D might increase aluminum absorption and toxicity, but this has only been reported in people with renal failure.

Read the full Vitamin D + Aluminum Hydroxide, Aspirin, Codeine Phosphate, Magnesium Hydroxide interaction

AminoglutethimideCytadren

Major

Aminoglutethimide belongs to Cns Depressants — the drug category that interacts with this product

How Aminoglutethimide interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Aminoglutethimide interaction

Aminophylline, Amobarbital, EphedrineAmesec

Major

Aminophylline, Amobarbital, Ephedrine belongs to Cns Depressants — the drug category that interacts with this product

How Aminophylline, Amobarbital, Ephedrine interacts with All Plant Protein Powder — through 1 ingredient. Tap an ingredient for the detail:

TryptophanCns Depressants Major

Interaction Summary

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.

Read the full Tryptophan + Aminophylline, Amobarbital, Ephedrine interaction

Each ingredient & the kinds of drugs it affects

For each ingredient in All Plant Protein Powder with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Vitamin D8 drug types · 715 drugs

Aluminum

Vitamin D might increase aluminum absorption and toxicity, but this has only been reported in people with renal failure.
The protein that transports calcium across the intestinal wall can also bind and transport aluminum. This protein is stimulated by vitamin D, which may therefore increase aluminum absorption. This mechanism may contribute to increased aluminum levels and toxicity in people with renal failure, when they take vitamin D and aluminum-containing phosphate binders chronically.

Likelihood Probable Evidence B

Atorvastatin (Lipitor)

Vitamin D might reduce absorption of atorvastatin.
A small, low-quality clinical study shows that taking vitamin D reduces levels of atorvastatin and its active metabolites by up to 55%. However, while atorvastatin levels decreased, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels did not substantially change. Atorvastatin is metabolized in the gut by CYP3A4 enzymes, and researchers theorized that vitamin D might induce CYP3A4, causing reduced levels of atorvastatin. However, this proposed mechanism was not specifically studied.

Likelihood Probable Evidence B

Calcipotriene (Dovonex)

Taking calcipotriene with vitamin D increases the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with vitamin D supplements might increase the risk of hypercalcemia.

Likelihood Probable Evidence D

Digoxin (Lanoxin)

Theoretically, hypercalcemia induced by high-dose vitamin D can increase the risk of arrhythmia from digoxin.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and digoxin concurrently.

Likelihood Possible Evidence D

Diltiazem (Cardizem, Others)

Theoretically, hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of diltiazem for arrhythmia.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically this could also occur with diltiazem. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and diltiazem concurrently.

Likelihood Probable Evidence B

Thiazide Diuretics

Theoretically, taking thiazide diuretics and high-dose vitamin D can increase the risk of hypercalcemia.
Thiazide diuretics decrease urinary calcium excretion, which could lead to hypercalcemia if vitamin D supplements are taken concurrently. This has been reported in people being treated with vitamin D for hypoparathyroidism, and also in elderly people with normal parathyroid function who were taking a thiazide, vitamin D, and calcium-containing antacids daily.

Likelihood Probable Evidence D

Verapamil (Calan, Others)

Hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of verapamil for arrhythmia.
Hypercalcemia due to high doses of vitamin D can reduce the effectiveness of verapamil in atrial fibrillation. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and verapamil concurrently.

Likelihood Probable Evidence B

Cytochrome P450 3A4 (Cyp3A4) Substrates

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
There is some concern that vitamin D might induce CYP3A4. In vitro research suggests that vitamin D induces CYP3A4 transcription. Additionally, observational research has found that increased UV light exposure and serum vitamin D levels are associated with decreased serum levels of CYP3A4 substrates such as tacrolimus and sirolimus, while no association between UV light exposure or vitamin D levels and levels of mycophenolic acid, a non-CYP3A4 substrate, was found. A small, low-quality clinical study shows that taking vitamin D reduces levels of the CYP3A4 substrate atorvastatin and its active metabolites by up to 55%; however, the clinical effects of atorvastatin were not reduced. While researchers theorized that vitamin D might induce CYP3A4, this proposed mechanism was not specifically studied.

Likelihood Possible Evidence D

Vitamin D full monograph & interactions

Tryptophan2 drug types · 394 drugs

Cns Depressants

Theoretically, concomitant use of L-tryptophan with CNS depressants might cause additive sedative effects.
Clinical research shows that L-tryptophan can cause fatigue and drowsiness.

Likelihood Probable Evidence B

Serotonergic Drugs

Theoretically, combining L-tryptophan with serotonergic drugs might cause additive serotonergic effects.
L-tryptophan is a precursor to serotonin. Theoretically, combining serotonergic drugs with L-tryptophan might increase the risk of serotonergic side effects, including serotonin syndrome and cerebral vasoconstrictive disorders.

Likelihood Possible Evidence D

Tryptophan full monograph & interactions

Sodium7 drug types · 205 drugs

Antihypertensive Drugs

Theoretically, a high intake of dietary sodium might reduce the effectiveness of antihypertensive drugs.
High intake of dietary sodium can increase systolic and diastolic blood pressure. Also, high intake of sodium may necessitate increased use of antihypertensive medications to achieve blood pressure control in some patients, such as those with chronic kidney disease.

Likelihood Probable Evidence A

Corticosteroids

Concomitant use of mineralocorticoids and some glucocorticoids with sodium supplements might increase the risk of hypernatremia.
Mineralocorticoids and some glucocorticoids (corticosteroids) cause sodium retention. This effect is dose-related and depends on mineralocorticoid potency. It is most common with hydrocortisone, cortisone, and fludrocortisone, followed by prednisone and prednisolone.

Likelihood Possible Evidence D

Didanosine (Videx)

Concomitant use of didanosine with additional sodium from dietary or supplemental sources may increase the risk of hypernatremia.
Didanosine formulations contain a significant amount of sodium.

Likelihood Probable Evidence C

Lithium

Altering dietary intake of sodium might alter the levels and clinical effects of lithium.
High sodium intake can reduce plasma concentrations of lithium by increasing lithium excretion. Reducing sodium intake can significantly increase plasma concentrations of lithium and cause lithium toxicity in patients being treated with lithium carbonate. Stabilizing sodium intake is shown to reduce the percentage of patients with lithium level fluctuations above 0.8 mEq/L. Patients taking lithium should avoid significant alterations in their dietary intake of sodium.

Likelihood Probable Evidence B

Sodium Phosphates

Theoretically, concomitant use of sodium phosphate with sodium supplements might increase the risk of hypernatremia.
Use of high doses (> 45 mL in 24 hours) of sodium phosphate, such as those used for bowel cleansing before surgery, can lead to serious electrolyte disturbances, including hypernatremia. The risk of hypernatremia is highest in the elderly and people with other risk factors for electrolyte disturbances.

Likelihood Possible Evidence D

Sodium-Containing Drugs

Concomitant use of sodium-containing drugs with additional sodium from dietary or supplemental sources may increase the risk of hypernatremia and long-term sodium-related complications.
The Chronic Disease Risk Reduction (CDRR) intake level of 2.3 grams of sodium daily indicates the intake at which it is believed that chronic disease risk increases for the apparently healthy population. Some medications contain high quantities of sodium. When used in conjunction with sodium supplements or high-sodium diets, the CDRR may be exceeded. Additionally, concomitant use may increase the risk for hypernatremia; this risk is highest in the elderly and people with other risk factors for electrolyte disturbances.

Likelihood Possible Evidence D

Tolvaptan (Samsca)

Theoretically, concomitant use of tolvaptan with sodium might increase the risk of hypernatremia.
Tolvaptan is a vasopressin receptor 2 antagonist that is used to increase sodium levels in patients with hyponatremia. Patients taking tolvaptan should use caution with the use of sodium salts such as sodium chloride.

Likelihood Probable Evidence C

Sodium full monograph & interactions

Calcium18 drug types · 168 drugs

Ceftriaxone (Rocephin)

Co-administration of intravenous calcium and ceftriaxone can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys.
Avoid administering intravenous calcium in any form, such as parenteral nutrition or Lactated Ringers, within 48 hours of intravenous ceftriaxone. Case reports in neonates show that administering intravenous ceftriaxone and calcium can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys. In several cases, neonates have died as a result of this interaction. So far there are no reports in adults; however, there is still concern that this interaction might occur in adults.

Likelihood Probable Evidence D

Dolutegravir (Tivicay)

Calcium seems to reduce levels of dolutegravir.
Advise patients to take dolutegravir either 2 hours before or 6 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium carbonate 1200 mg concomitantly with dolutegravir 50 mg reduces plasma levels of dolutegravir by almost 40%. Calcium appears to decrease levels of dolutegravir through chelation.

Likelihood Probable Evidence B

Elvitegravir (Vitekta)

Calcium seems to reduce levels of elvitegravir.
Advise patients to take elvitegravir either 2 hours before or 2 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium along with elvitegravir can reduce blood levels of elvitegravir through chelation.

Likelihood Probable Evidence B

Aluminum

Calcium citrate might increase aluminum absorption and toxicity. Other types of calcium do not increase aluminum absorption.
Calcium citrate can increase the absorption of aluminum when taken with aluminum hydroxide. The increase in aluminum levels may become toxic, particularly in individuals with kidney disease. However, the effect of calcium citrate on aluminum absorption is due to the citrate anion rather than calcium cation. Calcium acetate does not appear to increase aluminum absorption.

Likelihood Possible Evidence B

Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy)

Calcium might decrease levels of bictegravir/emtricitabine/tenofovir alafenamide by reducing its absorption when taken in a fasting state.
Advise patients that bictegravir/emtricitabine/tenofovir alafenamide and calcium can be taken together if taken with food. However, if taken on an empty stomach, bictegravir/emtricitabine/tenofovir alafenamide should not be taken with, or 2 hours after, calcium containing products.

Likelihood Probable Evidence D

Bisphosphonates

Calcium reduces the absorption of bisphosphonates.
Advise patients to take bisphosphonates at least 30 minutes before calcium, but preferably at a different time of day. Calcium supplements decrease absorption of bisphosphonates.

Likelihood Probable Evidence C

Calcipotriene (Dovonex)

Taking calcipotriene with calcium might increase the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with calcium supplements might increase the risk of hypercalcemia.

Likelihood Possible Evidence B

Digoxin (Lanoxin)

Using intravenous calcium with digoxin might increase the risk of fatal cardiac arrhythmias.
Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. However, one retrospective analysis of clinical data suggests that intravenous calcium does not increase the risk of dysrhythmias or mortality in patients receiving digoxin.

Likelihood Possible Evidence B

Diltiazem (Cardizem, Others)

Theoretically, calcium may reduce the therapeutic effects of diltiazem.
Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically, calcium might increase this risk of hypercalcemia and reduce the effectiveness of diltiazem.

Likelihood Probable Evidence D

Levothyroxine (Synthroid, Others)

Calcium seems to reduce the absorption and effectiveness of levothyroxine.
Advise patients to take levothyroxine and calcium supplements at least 4 hours apart. Calcium reduces levothyroxine absorption, probably by forming insoluble complexes. Calcium carbonate supplements reduce effectiveness of levothyroxine in patients with hypothyroidism.

Likelihood Probable Evidence B

Lithium

Theoretically, concomitant use of calcium and lithium may increase this risk of hypercalcemia.
Clinical research suggests that long-term use of lithium may cause hypercalcemia in 10% to 60% of patients. Theoretically, concomitant use of lithium and calcium supplements may further increase this risk.

Likelihood Possible Evidence B

Quinolone Antibiotics

Calcium seems to reduce the absorption of quinolone antibiotics.
Advise patients to take oral quinolones at least 2 hours before or 4-6 hours after calcium supplements or calcium-fortified foods. Taking calcium at the same time as oral quinolones can reduce quinolone absorption. Calcium binds to quinolones in the gut.

Likelihood Probable Evidence B

Raltegravir (Isentress)

Calcium may reduce levels of raltegravir.
Pharmacokinetic research shows that taking a single dose of calcium carbonate 3000 mg along with raltegravir 400 mg twice daily modestly decreases the mean area under the curve of raltegravir, but the decrease does not necessitate a dose adjustment of raltegravir. However, a case of elevated HIV-1 RNA levels and documented resistance to raltegravir has been reported for a patient taking calcium carbonate 1 gram three times daily plus vitamin D3 (cholecalciferol) 400 IU three times daily in combination with raltegravir 400 mg twice daily for 11 months. It is thought that calcium reduced raltegravir levels by chelation, leading to treatment failure.

Likelihood Possible Evidence B

Sotalol (Betapace)

Calcium seems to reduce the absorption of sotalol.
Advise patients to separate doses by at least 2 hours before or 4-6 hours after calcium. Calcium appears to reduce the absorption of sotalol, probably by forming insoluble complexes.

Likelihood Possible Evidence B

Tetracycline Antibiotics

Calcium seems to reduce the absorption of tetracycline antibiotics.
Advise patients to take oral tetracyclines at least 2 hours before, or 4-6 hours after calcium supplements. Taking calcium at the same time as oral tetracyclines can reduce tetracycline absorption. Calcium binds to tetracyclines in the gut.

Likelihood Probable Evidence C

Thiazide Diuretics

Taking calcium along with thiazides might increase the risk of hypercalcemia and renal failure.
Thiazides reduce calcium excretion by the kidneys. Using thiazides along with moderately large amounts of calcium carbonate increases the risk of milk-alkali syndrome (hypercalcemia, metabolic alkalosis, renal failure). Patients may need to have their serum calcium levels and/or parathyroid function monitored regularly.

Likelihood Probable Evidence C

Verapamil (Calan, Others)

Theoretically, calcium may reduce the therapeutic effects of verapamil.
Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically, use of calcium supplements may increase this risk of hypercalcemia and reduce the effectiveness of verapamil.

Likelihood Probable Evidence D

Calcium Channel Blockers

Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Intravenous calcium is used to decrease the effects of calcium channel blockers in the management of overdose. Intravenous calcium gluconate has been used before intravenous verapamil (Isoptin) to prevent or reduce the hypotensive effects without affecting the antiarrhythmic effects. But there is no evidence that dietary or supplemental calcium when taken orally interacts with calcium channel blockers.

Likelihood Unlikely Evidence D

Calcium full monograph & interactions

Iron13 drug types · 80 drugs

Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy)

Iron might decrease levels of bictegravir/emtricitabine/tenofovir alafenamide by reducing its absorption when taken in a fasting state.
Advise patients that bictegravir/emtricitabine/tenofovir alafenamide and iron can be taken together if taken with food. However, if taken on an empty stomach, bictegravir/emtricitabine/tenofovir alafenamide should not be taken with, or 2 hours after, iron containing products.

Likelihood Probable Evidence D

Bisphosphonates

Iron reduces the absorption of bisphosphonates.
Advise patients that doses of bisphosphonates should be separated by at least two hours from doses of all other medications, including supplements such as iron. Divalent cations, including iron, can decrease absorption of bisphosphonates by forming insoluble complexes in the gastrointestinal tract.

Likelihood Probable Evidence D

Denosumab (Prolia, Others)

Administration of intravenous iron within one month of denosumab administration might increase the risk of severe hypophosphatemia and hypocalcemia.
A case of severe hypocalcemia (albumin corrected calcium 6.88 mg/dL, ionized calcium 3.68 mg/dL) and hypophosphatemia (<0.5 mg/dL) with respiratory acidosis, QT interval prolongation, and nonsustained ventricular tachycardia was reported in a 76-year-old male who had received an iron polymaltose infusion within 2 weeks of a subcutaneous injection of denosumab. Serum parathyroid hormone was also elevated (348 pg/mL). Subsequent iron infusions with iron polymaltose and ferric carboxymaltose were followed by transient hypophosphatemia, but without hypocalcemia. Additionally, a literature review describes 6 additional cases of hypophosphatemia and hypocalcemia in patients 52-92 years of age who had been administered intravenous iron as either ferric carboxymaltose or iron polymaltose and subcutaneous denosumab within 1-4 weeks of each other.

Likelihood Possible Evidence D

Dolutegravir (Tivicay)

Iron might decrease dolutegravir levels by reducing its absorption.
Advise patients to take dolutegravir at least 2 hours before or 6 hours after taking iron. Pharmacokinetic research shows that iron can decrease the absorption of dolutegravir from the gastrointestinal tract through chelation. When taken under fasting conditions, a single dose of ferrous fumarate 324 mg orally along with dolutegravir 50 mg reduces overall exposure to dolutegravir by 54%.

Likelihood Probable Evidence B

Integrase Inhibitors

Theoretically, taking iron along with integrase inhibitors might decrease the levels and clinical effects of these drugs.
Iron is a divalent cation. There is concern that iron may decrease the absorption of integrase inhibitors from the gastrointestinal tract through chelation. One pharmacokinetic study shows that iron can decrease blood levels of the specific integrase inhibitor dolutegravir through chelation. Also, other pharmacokinetic research shows that other divalent cations such as calcium can decrease the absorption and levels of some integrase inhibitors through chelation.

Likelihood Possible Evidence D

Levodopa

Iron might decrease levodopa levels by reducing its absorption.
Advise patients to separate doses of levodopa and iron as much as possible. There is some evidence in healthy people that iron forms chelates with levodopa, reducing the amount of levodopa absorbed by around 50%. The clinical significance of this hasn't been determined.

Likelihood Probable Evidence B

Levothyroxine (Synthroid, Others)

Iron might decrease levothyroxine levels by reducing its absorption.
Advise patients to separate levothyroxine and iron doses by at least 2 hours. Iron can decrease the absorption and efficacy of levothyroxine by forming insoluble complexes in the gastrointestinal tract.

Likelihood Probable Evidence B

Methyldopa (Aldomet)

Iron might decrease methyldopa levels by reducing its absorption.
Advise patients to separate methyldopa and iron doses by at least 2 hours. Iron can decrease the absorption of methyldopa from the gastrointestinal tract through chelation, resulting in increases in blood pressure.

Likelihood Probable Evidence B

Mycophenolate Mofetil (Cellcept)

Theoretically, iron might decrease mycophenolate mofetil levels by reducing its absorption.
Advise patients to take iron 4-6 hours before, or 2 hours after, mycophenolate mofetil. It has been suggested that a decrease of absorption is possible, probably by forming nonabsorbable chelates. However, mycophenolate pharmacokinetics are not affected by iron supplementation in available clinical research.

Likelihood Unlikely Evidence D

Penicillamine (Cuprimine, Depen)

Iron might decrease penicillamine levels by reducing its absorption.
Advise patients to separate penicillamine and iron doses by at least 2 hours. Oral iron supplements can reduce absorption of penicillamine by 30% to 70%, probably due to chelate formation. In people with Wilson's disease, this interaction has led to reduced efficacy of penicillamine.

Likelihood Probable Evidence D

Quinolone Antibiotics

Iron might decrease levels of quinolone antibiotics by reducing their absorption.
Advise patients to separate quinolone antibiotics and iron doses by at least 2 hours. Iron decreases the absorption of quinolones due to formation of insoluble complexes in the gastrointestinal tract.

Likelihood Probable Evidence D

Tetracycline Antibiotics

Iron might decrease levels of tetracycline antibiotics by reducing their absorption.
Advise patients to take iron at least 2 hours before or 4 hours after tetracycline antibiotics. Concomitant use can decrease absorption of tetracycline antibiotics from the gastrointestinal tract by 50% to 90%.

Likelihood Probable Evidence D

Chloramphenicol

Theoretically, taking chloramphenicol with iron might reduce the response to iron therapy in iron deficiency anemia.
Chloramphenicol interferes with erythrocyte maturation. However, since chloramphenicol isn't usually taken for prolonged periods, this isn't likely to be clinically significant.

Likelihood Unlikely Evidence D

Iron full monograph & interactions

Potassium3 drug types · 62 drugs

Ace Inhibitors (Aceis)

Using ACEIs with high doses of potassium increases the risk of hyperkalemia.
ACEIs block the actions of the renin-angiotensin-aldosterone system and reduce potassium excretion. Concomitant use of these drugs with potassium supplements increases the risk of hyperkalemia. However, concomitant use of these drugs with moderate dietary potassium intake (about 3775-5200 mg daily) does not increase serum potassium levels.

Likelihood Likely Evidence C

Angiotensin Receptor Blockers (Arbs)

Using ARBs with high doses of potassium increases the risk of hyperkalemia.
ARBs block the actions of the renin-angiotensin-aldosterone system and reduce potassium excretion. Concomitant use of these drugs with potassium supplements increases the risk of hyperkalemia. However, concomitant use of these drugs with moderate dietary potassium intake (about 3775-5200 mg daily) does not increase serum potassium levels.

Likelihood Likely Evidence C

Potassium-Sparing Diuretics

Concomitant use increases the risk of hyperkalemia.
Using potassium-sparing diuretics with potassium supplements increases the risk of hyperkalemia.

Likelihood Likely Evidence C

Potassium full monograph & interactions

Tyrosine2 drug types · 21 drugs

Levodopa

Theoretically, tyrosine might decrease the effectiveness of levodopa.
Tyrosine and levodopa compete for absorption in the proximal duodenum by the large neutral amino acid (LNAA) transport system. Advise patients to separate doses of tyrosine and levodopa by at least 2 hours.

Likelihood Probable Evidence D

Thyroid Hormone

Theoretically, tyrosine might have additive effects with thyroid hormone medications.
Tyrosine is a precursor to thyroxine and might increase levels of thyroid hormones.

Likelihood Probable Evidence D

Tyrosine full monograph & interactions

Phenylalanine3 drug types · 16 drugs

Levodopa

Phenylalanine, especially in high doses, can reduce the effectiveness of levodopa.
Phenylalanine competes with levodopa for carrier-mediated transport into the brain. The resulting reduction in levels of levodopa in the brain can exacerbate tremor, rigidity, and the "on-off" phenomenon in patients with Parkinson disease.

Likelihood Probable Evidence B

Baclofen

Concomitant intake of phenylalanine may reduce the intestinal absorption of baclofen.
Phenylalanine and baclofen share the same intestinal carrier for absorption; phenylalanine competitively inhibits the absorption of baclofen, reducing its plasma levels.

Likelihood Possible Evidence D

Monoamine Oxidase Inhibitors (Maois)

Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
L-phenylalanine is metabolized to tyrosine. Some evidence suggests that L-phenylalanine, given with the non-selective MAOI pargyline, might prevent the elimination of tyramine, increasing the risk of hypertensive crisis. However, this was not reported in a small number of patients when using L-phenylalanine with the partially selective MAO-B inhibitor, selegiline.

Likelihood Possible Evidence D

Phenylalanine full monograph & interactions

Threonine1 drug type · 3 drugs

Nmda Antagonists

Theoretically, threonine might decrease the effects of NMDA antagonists.
Threonine increases central nervous system (CNS) glycine levels. Glycine seems to bind a site on NMDA receptors and enhance the activity of the receptors.

Likelihood Likely Evidence B

Threonine full monograph & interactions

Glycine1 drug type · 1 drug

Clozapine (Clozaril)

Theoretically, glycine might decrease the effectiveness of clozapine.
One small clinical study in patients with schizophrenia shows that adding glycine to clozapine therapy worsens symptoms of schizophrenia when compared with clozapine alone. The mechanism of this interaction is unclear.

Likelihood Probable Evidence B

Glycine full monograph & interactions

Lysine1 drug type · 1 drug

5-Ht4 Agonists

Theoretically, lysine may reduce the effects of 5-HT4 agonists.
Animal research suggests that L-lysine is a partial serotonin receptor 4 (5-HT4) antagonist and inhibits diarrhea induced by the 5-HT4 agonist, 5-hydroxytryptophane.

Likelihood Unlikely Evidence D

Lysine full monograph & interactions

The maker

Brand information

Manufacturer and brand details for All Plant Protein Powder, from the product label.

Nutrilite

See all Nutrilite products

Name: Amway Corp.
City: Ada
State: MI
ZipCode: 49355
Phone Number: 1-800-253-6500
Web Address: Amway.com/Nutrilite

Pharmacist Counseling Corner

All Plant Protein Powder by Nutrilite: Common Questions

Does All Plant Protein Powder by Nutrilite interact with any medications?

Yes. Based on its ingredients, All Plant Protein Powder has a known interaction with 1,138 medications, including 263 rated major. Use the checker to see how it interacts with a specific drug.

How can one product interact with so many drugs?

All Plant Protein Powder contains 24 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.

Where does this information come from?

The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.

Can I take this if I'm on blood pressure medication?

Not without checking first. The sodium in this product can reduce how well blood pressure drugs work, and the potassium can interact with certain blood pressure meds like ACE inhibitors or ARBs. Your pharmacist can tell you whether your specific medication is affected.

Is this safe during pregnancy?

Some ingredients are fine in pregnancy — calcium, potassium, and iron at recommended amounts are likely safe. But phenylalanine is unsafe at supplemental doses in pregnancy, and aspartic acid, tryptophan, and serine don't have enough data. Talk with your doctor or pharmacist before starting, especially since this is a multi-ingredient product.

Will this help me build muscle?

The data we hold don't establish that the amino acids in this product are effective for muscle strength or athletic performance. It's a protein source, and protein does support muscle — but whether this specific blend is better than other protein powders, the evidence doesn't say.

What does L-tryptophan in this product do?

L-tryptophan is an amino acid your body uses to make serotonin, which affects mood and sleep. The evidence suggests it may not be effective for depression. It can cause drowsiness, and it interacts with antidepressants and sedatives, so mention it to your pharmacist if you take those.

Can I take this with my thyroid medication?

Iron in this powder can reduce how well levothyroxine (Synthroid) is absorbed. If you take thyroid medication, separate your doses by at least 2 hours — take one in the morning and the other much later — and ask your pharmacist to monitor whether your dosage needs adjusting.

Does this product have fillers?

Yes. In addition to the active amino acids and minerals, it contains soy protein isolate, wheat protein, pea protein, lecithin, and silicon dioxide, which are inactive ingredients that help make the powder work as a product.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if All Plant Protein Powder is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Go deeper

The Full Monographs Behind All Plant Protein Powder’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Sodium

Interacts with 205 drugs

Sodium is an essential mineral and electrolyte your body needs to balance fluids, support nerves, and help muscles work. Most people in modern diets get more than enough—often too much—from...

Read the full Sodium monograph → Herb & supplement monograph

Potassium

Interacts with 62 drugs

Potassium is an essential mineral your body needs for nerve signals, muscle function, and a steady heartbeat, and most people get enough from a balanced diet rich in fruits and vegetables. P...

Read the full Potassium monograph → Herb & supplement monograph

Calcium

Interacts with 168 drugs

Calcium is an essential mineral your body needs for strong bones, nerve signaling, and muscle function, and supplements can help fill gaps when diet falls short. Most people do best getting...

Read the full Calcium monograph → Herb & supplement monograph

Iron

Interacts with 80 drugs

Iron is an essential mineral your body needs to make hemoglobin and carry oxygen in the blood. Supplements are mainly useful for treating or preventing iron deficiency and iron-deficiency an...

Read the full Iron monograph → Herb & supplement monograph

Vitamin D

Interacts with 715 drugs

Vitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people, especially those with low sun exposure,...

Read the full Vitamin D monograph → Herb & supplement monograph

Glycine

Interacts with 1 drug

Glycine is a non-essential amino acid your body makes on its own and that also appears in protein-rich foods. It is most studied for improving sleep quality, where early research is promisin...

Read the full Glycine monograph → Herb & supplement monograph

Aspartic Acid

Aspartic acid is a common amino acid your body makes on its own and gets from protein-rich foods, so a true deficiency is rare. D-aspartic acid is heavily marketed for boosting testosterone...

Read the full Aspartic Acid monograph → Herb & supplement monograph

L-tryptophan

Interacts with 394 drugs

L-tryptophan is an essential amino acid the body uses to make serotonin and melatonin, and people take it to support sleep and mood. The evidence for supplement use is limited and mixed, and...

Read the full L-tryptophan monograph → Herb & supplement monograph

Methionine

Methionine is an essential amino acid that your body needs for protein building and many basic chemical reactions. Most people get enough from a normal diet, and supplements are generally no...

Read the full Methionine monograph → Herb & supplement monograph

Serine

Serine is an amino acid your body can make on its own and also gets from protein-rich foods, so most people do not need a supplement. L-serine has been studied for certain neurological condi...

Read the full Serine monograph → Herb & supplement monograph

Tyrosine

Interacts with 21 drugs

L-tyrosine is an amino acid your body uses to make brain chemicals like dopamine and norepinephrine. Some studies suggest it may help mental performance during short-term stress, sleep loss,...

Read the full Tyrosine monograph → Herb & supplement monograph

Histidine

Histidine is an essential amino acid your body needs to build proteins and to make compounds like histamine and carnosine. Most people get enough from a normal diet, and good-quality researc...

Read the full Histidine monograph → Herb & supplement monograph

Lysine

Interacts with 1 drug

Lysine is an essential amino acid your body cannot make on its own, so it must come from food or supplements. People most often take extra lysine to try to prevent or shorten cold sores, but...

Read the full Lysine monograph → Herb & supplement monograph

Phenylalanine

Interacts with 16 drugs

Phenylalanine is an essential amino acid the body uses to make brain chemicals like dopamine and norepinephrine. Some people take it for mood, vitiligo, or pain, but the evidence is mostly l...

Read the full Phenylalanine monograph → Herb & supplement monograph

Threonine

Interacts with 3 drugs

Threonine is an essential amino acid your body needs but cannot make, so you must get it from food or supplements. Most people get plenty from a normal diet, and high-quality evidence for ta...

Read the full Threonine monograph → Herb & supplement monograph

Proline

Proline is a non-essential amino acid that your body can make on its own and that you also get from protein-rich foods. It is a key building block of collagen, but strong human evidence that...

Read the full Proline monograph →

Sources

Sources & How We Checked

All Plant Protein Powder's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

NIH Dietary Supplement Label Database (DSLD) — The official product label on file for this supplement.
Natural Medicines (Therapeutic Research Center) — Evidence-graded clinical reference behind the ingredient interaction data.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 294 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Sodium 38 references

Garabedian-Ruffalo SM, Ruffalo RL. Drug and nutrient interactions. Am Fam Physician 1986;33:165-74.
Food and Drug Administration Science Background: Safety of Sodium Phosphates Oral Solution. September 17, 2001. Available at: http://www.fda.gov/cder/drug/safety/sodiumphospate.htm
Coton T, Mallaret C, Coilliot C, Carre D, Guisset M. Severe acute ulcerated gastritis induced by salt. Presse Med 2009;38(3):499-500. PubMed
Frings-Meuthen P, Buehlmeier J, Baecker N, et al. High sodium chloride intake exacerbates immobilization-induced bone resorption and protein losses. J Appl Physiol 2011;111(2):537-542. PubMed
Frings-Meuthen P, Baecker N, Heer M. Low-grade metabolic acidosis may be the cause of sodium chloride-induced exaggerated bone resorption. J Bone Miner Res 2008;23(4):517-524. PubMed
Alam S, Johnson AG. A meta-analysis of randomised controlled trials (RCT) among healthy normotensive and essential hypertensive elderly patients to determine the effect of high salt (NaCl) diet of blood pressure. J Hum Hypertens 1999;13(6):367-74.
Boudville N, Ward S, Benaroia M, House AA. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens 2005;18(10):1300-5. PubMed
Bennett WM. Drug interactions and consequences of sodium restriction. Am J Clin Nutr 1997;65(2 Suppl):678S-681S. PubMed
Okusa MD, Crystal LJ. Clinical manifestations and management of acute lithium intoxication. Am J Med 1994;97(4):383-9. PubMed
Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, DC: National Academy Press, 2005. Available at: http://www.nap.edu/openbook.php?record_id=10925. DOI
D'Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr 2012;31(4):489-98. PubMed
Goldsmith SR. Hyponatremia in heart failure: time for a trial. J Card Fail 2013;19(6):398-400. PubMed
Willocks L, Brettle R, Keen J, Valentine C, Pinching AJ. Formulations of didanosine (ddI) and salt overload. Lancet 1992;339(8786):190.
Chen L, Zhang Z, Chen W, Whelton PK, Appel LJ. Lower Sodium Intake and Risk of Headaches: Results From the Trial of Nonpharmacologic Interventions in the Elderly. Am J Public Health. 2016;106(7):1270-5. PubMed
Cook NR, Appel LJ, Whelton PK. Lower levels of sodium intake and reduced cardiovascular risk. Circulation. 2014;129(9):981-9. PubMed
Cook NR, Appel LJ, Whelton PK. Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of Hypertension Prevention. J Am Coll Cardiol. 2016;68(15):1609-1617. PubMed
Mente A, O'Donnell M, Rangarajan S, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet. 2016;388(10043):465-75. PubMed
Moosavian SP, Haghighatdoost F, Surkan PJ, Azadbakht L. Salt and obesity: a systematic review and meta-analysis of observational studies. Int J Food Sci Nutr. 2017;68(3):265-277. PubMed
O'Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371(7):612-23. DOI
Poggio R, Gutierrez L, Matta MG, Elorriaga N, Irazola V, Rubinstein A. Daily sodium consumption and CVD mortality in the general population: systematic review and meta-analysis of prospective studies. Public Health Nutr. 2015;18(4):695-704. PubMed
Stallings VA, Harrison M, Oria M; Committee to Review the Dietary Reference Intakes for Sodium and Potassium, Food and Nutrition Board, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Washington (DC): National Acad
Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced Salt Intake for Heart Failure: A Systematic Review. JAMA Intern Med. 2018 Dec 1;178(12):1693-1700. PubMed
Yancy CW. Sodium Restriction in Heart Failure: Too Much Uncertainty-Do the Trials. JAMA Intern Med. 2018 Dec 1;178(12):1700-1701. PubMed
He FJ, Campbell NRC, Ma Y, MacGregor GA, Cogswell ME, Cook NR. Errors in estimating usual sodium intake by the Kawasaki formula alter its relationship with mortality: implications for public health. Int J Epidemiol. 2018;47(6):1784-1795. PubMed
Murthy K, Ondrey GJ, Malkani N, et al. THE EFFECTS OF HYPONATREMIA ON BONE DENSITY AND FRACTURES: A SYSTEMATIC REVIEW AND META-ANALYSIS. Endocr Pract. 2019;25(4):366-378. PubMed
Messerli FH, Hofstetter L, Syrogiannouli L, et al. Sodium intake, life expectancy, and all-cause mortality. Eur Heart J 2021;42(21):2103-2112. PubMed
Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2020;12(12):CD004022. PubMed
Giatti S, Santos RB, Aielo AN, et al. Association of sodium with obstructive sleep apnea. The ELSA-Brasil study. Ann Am Thorac Soc 2021;18(3):502-510. PubMed
Nan X, Lu H, Wu J, et al. The interactive association between sodium intake, alcohol consumption and hypertension among elderly in northern China: a cross-sectional study. BMC Geriatr 2021;21(1):135. PubMed
Kyozuka H, Fukusda T, Murata T, et al. Impact of preconception sodium intake on hypertensive disorders of pregnancy: The Japan Environment and Children's study. Pregnancy Hypertens 2021;23:66-72. PubMed
Zhao L, Ogden CL, Yang Q, et al. Association of usual sodium intake with obesity among US children and adolescents, NHANES 2009-2016. Obesity (Silver Spring) 2021;29(3):587-594. PubMed
Ma Y, He FJ, Sun Q, et al. 24-Hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med 2022;386(3):252-263. PubMed
Liu J, Yang X, Zhang P, et al. Association of urinary sodium excretion and left ventricular hypertrophy in people with type 2 diabetes mellitus: A cross-sectional study. Front Endocrinol (Lausanne) 2021;12:728493. PubMed
Filippini T, Malavolti M, Whelton PK, Vinceti M. Sodium intake and risk of hypertension: A systematic review and dose-response meta-analysis of observational cohort studies. Curr Hypertens Rep 2022;24(5):133-144. PubMed
Wang DD, Li Y, Nguyen XT, et al. Dietary sodium and potassium intake and risk of non-fatal cardiovascular diseases: The million veteran program. Nutrients 2022;14(5):1121. PubMed
Kwak JH, Park CH, Eun CS, et al. The associations of dietary intake of high sodium and low zinc with gastric cancer mortality: A prospective cohort study in Korea. Nutr Cancer 2022;74(10):3501-3508. PubMed
George S, Maiti R, Mishra BR, Jena M, Mohapatra D. Effect of regulated add-on sodium chloride intake on stabilization of serum lithium concentration in bipolar disorder: A randomized controlled trial. Bipolar Disord 2023;25(1):66-75. PubMed
Zhou TL, Schütten MTJ, Kroon AA, et al. Urinary Sodium Excretion and Salt Intake Are Not Associated With Blood Pressure Variability in a White General Population. J Am Heart Assoc 2023;12(1):e026578. PubMed

See these in context on the Sodium monograph →

Potassium 12 references

McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Gennaro A. Remington: The Science and Practice of Pharmacy. 19th ed. Lippincott: Williams & Wilkins, 1996.
Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997;277:1624-32. PubMed
Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., and Krumholz, H. M. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from ra DOI
Altieri, P. I., Herrero, C., Suero, R., and Ortiz, A. Bleeding duodenal ulcer in a patient taking slow-releasing potassium tablets. Bol.Asoc.Med P.R. 1977;69(8):276.
Raf, L. E. Enteric-coated potassium chloride tablets and ulcer of the small intestine. Acta Chir Scand Suppl 1967;(374):1-87.
Potassium chloride oral solution [package insert]. Allentown, PA: Lehigh Valley Technologies, Inc.; 2014.
Potassium chloride injection [package insert]. Lake Forest, IL: Hospira Inc.; 2009.
Patel RB, Tannenbaum S, Viana-Tejedor A, et al. Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care 2017 Feb;6(1):1 PubMed
Malta D, Arcand J, Ravindran A, Floras V, Allard JP, Newton GE. Adequate intake of potassium does not cause hyperkalemia in hypertensive individuals taking medications that antagonize the renin angiotensin aldosterone system. Am J Clin Nutr 2016 Oct;104(4 PubMed
Keskin M, Kaya A, Tatlisu MA, et al. The effect of serum potassium level on in-hospital and long-term mortality in ST elevation myocardial infarction. Int J cardiol. 2016 Oct 15;221:505-10.
Stallings VA, Harrison M, Oria M; Committee to Review the Dietary Reference Intakes for Sodium and Potassium, Food and Nutrition Board, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Washington (DC): National Acad

See these in context on the Potassium monograph →

Calcium 62 references

Shils M, Olson A, Shike M. Modern Nutrition in Health and Disease. 8th ed. Philadelphia, PA: Lea and Febiger, 1994.
Hernandez-Avila M, Gonzalez-Cossio T, Hernandez-Avila JE, et al. Dietary calcium supplements to lower blood lead levels in lactating women: a randomized placebo-controlled trial. Epidemiology 2003;14:206-12.. PubMed
Thys-Jacobs S, Ceccarelli S, Bierman A, et al. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med 1989;4:183-9. PubMed
Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57:855-70.
Clemens JD, Feinstein AR. Calcium carbonate and constipation: a historical review of medical mythopoeia. Gastroenterology 1977;72:957-61. DOI
Saunders D, Sillery J, Chapman R. Effect of calcium carbonate and aluminum hydroxide on human intestinal function. Dig Dis Sci 1988;33:409-13. PubMed
Friedman PA, Bushinsky DA. Diuretic effects on calcium metabolism. Semin Nephrol 1999;19:551-6.
Koo WK, Walters JC, Esterlitz J, et al. Maternal calcium supplementation and fetal bone mineralization. Obstet Gynecol 1999;94:577-82. DOI
Raman L, Rajalakshmi K, Krishnamachari KAVR, et al. Effect of calcium supplementation to undernourished mothers during pregnancy on the bone density of the neonates. Am J Clin Nutr 1978; 31:466-9. DOI
Murry JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietician. J Am Diet Assoc 1991;91:66-73.
Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer. Cancer Causes Control 1998;9:559-66.
Butner LE, Fulco PP, Feldman G, et al. Calcium carbonate-induced hypothyroidism. Ann Intern Med 2000:132:595. PubMed
Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA 1998;279:750. PubMed
Moser LR, Smythe MA, Tisdale JE. The use of calcium salts in the prevention and management of verapamil-induced hypotension. Ann Pharmacother 2000;34:622-9. PubMed
Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000;283:2822-5. PubMed
Kahela P, Anttila M, Tikkanen R, Sundquist H. Effect of food, food constituents and fluid volume on the bioavailability of sotalol. Acta Pharmacol Toxicol (Copenh) 1979;44:7-12.. PubMed
Pletz MW, Petzold P, Allen A, et al. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003;47:2158-60.. PubMed
Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
Decktor DL, Robinson M, Maton PN, et al. Effects of aluminum/magnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn. Am J Ther 1995;2:546-52. PubMed
Simoneau G. Absence of rebound effect with calcium carbonate. Eur J Drug Metab Pharmacokinet 1996;21:351-7. PubMed
Peters ML, Leonard M, Licata AA. Role of alendronate and risedronate in preventing and treating osteoporosis. Cleve Clin J Med 2001;68:945-51. PubMed
Bourke JF, Mumford R, Whittaker P, et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997;37:929-34.
Gueguen L, Pointillart A. The bioavailability of dietary calcium. J Am Coll Nutr 2000;19:119s-136s. PubMed
Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J 1999;75:554-6. PubMed
Bania TC, Blaufeux B, Hughes S, et al. Calcium and digoxin vs. calcium alone for severe verapamil toxicity. Acad Emerg Med 2000;7:1089-96. PubMed
Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 2005;81:1147-54. PubMed
Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2004;(1):CD003548. PubMed
Tavani A, Bertuccio P, Bosetti C, et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 2005;48:27-33. PubMed
Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:203-10. PubMed
Rocephin (ceftriaxone) and calcium interaction. Pharmacist's Letter / Prescriber's Letter 2007;23(10):231005.
Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised control trial. BMJ 2008;336:262-6.
Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691. PubMed
Calcium supplementation and vascular events. Pharmacist's Letter / Prescriber's Letter 2008;24(3):240306.
Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-11. PubMed
Bradley JS, Wassel RT, Lee L, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609-13. PubMed
Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42(6):1253-9. PubMed
Neuhofel, A. L., Wilton, J. H., Victory, J. M., Hejmanowsk, L. G., and Amsden, G. W. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42(4):461-466. DOI
Dickinson, H. O., Nicolson, D. J., Cook, J. V., Campbell, F., Beyer, F. R., Ford, G. A., and Mason, J. Calcium supplementation for the management of primary hypertension in adults. Cochrane.Database.Syst.Rev. 2006;(2):CD004639. PubMed
Jones, B. J. and Twomey, P. J. Requesting patterns for serum calcium concentration in patients on long-term lithium therapy. Int J Clin Pract. 2009;63(1):170-172. PubMed
Levine, M., Nikkanen, H., and Pallin, D. J. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg.Med. 2011;40(1):41-46. PubMed
Castelo-Branco, C., Ciria-Recasens, M., Cancelo-Hidalgo, M. J., Palacios, S., Haya-Palazuelos, J., Carbonell-Abello, J., Blanch-Rubio, J., Martinez-Zapata, M. J., Manasanch, J., and Perez-Edo, L. Efficacy of ossein-hydroxyapatite complex compared with ca
Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation i
Chung M, Tang AM, Fu Z. Calcium Intake and Cardiovascular Disease Risk: An Updated Systematic Review and Meta-analysis. Ann Intern Med. 2016 Oct 25. PubMed
Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. 1990;38(5):937-41. PubMed
Lewis JR, Radavelli-Bagatini S, Rejnmark L, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res PubMed
Jalloh MA, Gregory PJ, Hein D, et al. Dietary supplement interactions with antiretrovirals: a systematic review. Int J STD AIDS. 2017 Jan;28(1):4-15. PubMed
Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
Grove ML, Cook D. Calcium and heart attacks. Doesn't apply to most calcium prescriptions. BMJ. 2010;341:c5003. PubMed
Insentress [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2014.
Roberts JL, Kiser JJ, Hindman JT, Meditz AL. Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration. Pharmacotherapy 2011;31(10):298e-302e. DOI
Vitekta [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2014.
Storan ER, O'Gorman SM, Murphy A, Laing M. Case Report of Calciphylaxis Secondary to Calcium and Vitamin D3 Supplementation. J Cutan Med Surg. 2017;21(2):162-163. DOI
Jenkins DJA, Spence JD, Giovannucci EL, et al. Supplemental vitamins and minerals for CVD prevention and treatment. J Am Coll Cardiol 2018;71(22):2570-84. PubMed
Borkenhagen JF, Connor EL, Stafstrom CE. Neonatal hypocalcemic seizures due to excessive maternal calcium ingestion. Pediatr Neurol 2013;48(6):469-71. PubMed
WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/ anc-positive-pregnancy-experience/en/).
Aune D, Navarro Rosenblatt DA, Chan DS, et al. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr. 2015;101(1):87-117. PubMed
Lan T, Park Y, Colditz GA, et al. Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2020;31(10):891-904. PubMed
Zhang Y, Li Y, Liu J, et al. Association of Vitamin D or Calcium Supplementation with Cardiovascular Outcomes and Mortality: A Meta-Analysis with Trial Sequential Analysis. J Nutr Health Aging 2021;25(2):263-270. PubMed
Myung SK, Kim HB, Lee YJ, Choi YJ, Oh SW. Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials. Nutrients 2021;13(2):368. PubMed
Hetaimish B. Neonatal Calcinosis Cutis After Treatment of Hypocalcemia with Calcium Gluconate: A Report of 2 Cases. Am J Case Rep 2024;25:e943397. PubMed
US Food and Drug Administration (FDA). Biktarvy Prescribing Information. October 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210251Orig1s020lbl.pdf. Accessed July 16, 2025.

See these in context on the Calcium monograph →

Iron 72 references

McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Bruner AB, Joffe A, Duggan AK, et al. Randomized study of cognitive effects of iron supplementation in non- anaemic iron-deficient adolescent girls. Lancet 1996;348:992-6.
Ullen H, Augustsson K, Gustavsson C, Steineck G. Supplementary iron intake and risk of cancer: reversed causality? Cancer Lett 1997;114:215-6.
Reunanen A, Takkunen H, Knekt P, et al. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med 1995;238:223-30. PubMed
Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr 1999;69:250-5.
Rehman A, Collis CS, Yang M, et al. The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. Biochem Biophys Res Comm 1998;246:293-8. PubMed
Klipstein-Grobusch K, Grobbee DE, den Breeijen JH, et al. Dietary iron and risk of myocardial infarction in the Rotterdam Study. Am J Epidemiol 1999;149:421-8. PubMed
Hansten PD, Horn JR. Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics Inc., 1997 and updates.
Tatro DS, ed. Drug Interactions Facts. Facts and Comparisons Inc., St. Louis, MO. 1999.
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
Campbell N, Paddock V, Sundaram R. Alteration of methyldopa absorption, metabolism, and blood pressure control by ferrous sulfate and ferrous gluconate. Clin Pharmacol Ther 1988;43:381-6..
Schumann K, Borch-Iohnsen B, Hentze MW, Marx JJ. Tolerable upper intakes for dietary iron set by the US Food and Nutrition Board (commentary). Am J Clin Nutr 2002;76:499-500. PubMed
Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998;97:1461-6.. PubMed
Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992;86:803-11.. PubMed
Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: Chelation as a possible mechanism. Clin Pharmacol Ther 1989;45:220-5.. PubMed
Campbell NRC, Hasinoff BB, Stalts H, et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Int Med 1992;117:1010-3.. PubMed
Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997;96:3300-07. PubMed
Comparison of oral iron supplements. Pharmacist's Letter / Prescriber's Letter 2008;24(8):240811.
Tran T., Wax J. R., Philput C., Steinfeld J. D., Ingardia C. J. Intentional iron overdose in pregnancy--management and outcome. J Emerg Med 2000;18(2):225-228. PubMed
Toblli J. E., Brignoli, R. Iron(III)-hydroxide polymaltose complex in iron deficiency anemia / review and meta-analysis. Arzneimittelforschung 2007;57(6A):431-438. PubMed
Köpcke W., Sauerland M. C. Meta-analysis of efficacy and tolerability data on iron proteinsuccinylate in patients with iron deficiency anemia of different severity. Arzneimittelforschung 1995;45(11):1211-1216.
Campbell N. R., Campbell R. R., Hasinoff B. B. Ferrous sulfate reduces methyldopa absorption: methyldopa: iron complex formation as a likely mechanism. Clin Invest Med 1990;13(6):329-332.
Morii M., Ueno K., Ogawa A., Kato R., Yoshimura H., Wada K., Hashimoto H., Takada M., Tanaka K., Nakatani T., Shibakawa M. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000;68(6):613-616. PubMed
Gelone D. K., Park J. M., Lake K. D. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. Pharmacotherapy 2007;27(9):1272-1278. PubMed
Ducray P. S., Banken L., Gerber M., Boutouyrie B., Zandt H. Absence of an interaction between iron and mycophenolate mofetil absorption. Br J Clin Pharmacol 2006;62(4):492-495. PubMed
Lorenz M., Wolzt M., Weigel G., Puttinger H., Hörl W. H., Födinger M., Speiser W., Sunder-Plassmann G. Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. Am J Kidney Dis 2004;43(6):1098-1103. PubMed
Osman M. A., Patel R. B., Schuna A., Sundstrom W. R., Welling P. G. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. Clin Pharmacol Ther 1983;33(4):465-470. PubMed
Michael, B., Coyne, D. W., Fishbane, S., Folkert, V., Lynn, R., Nissenson, A. R., Agarwal, R., Eschbach, J. W., Fadem, S. Z., Trout, J. R., Strobos, J., and Warnock, D. G. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compar
Zhang, X., Ouyang, J., Wieczorek, R., and DeSoto, F. Iron medication-induced gastric mucosal injury. Pathol.Res Pract 2009;205(8):579-581. PubMed
Barbieri, P. G. [To-day exposure to occupational carcinogens and their effects. The experience of the rubber industry, iron metallurgy, asphalt work and aviculture]. Epidemiol.Prev 2009;33(4-5 Suppl 2):94-105.
Macedo, A. and Cardoso, S. [Routine iron supplementation in pregnancy]. Acta Med Port. 2010;23(5):785-792.
Bastide, N. M., Pierre, F. H., and Corpet, D. E. Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved. Cancer Prev Res (Phila) 2011;4(2):177-184. PubMed
Stevens, R. G. Iron and the risk of cancer. Med Oncol Tumor Pharmacother. 1990;7(2-3):177-181. PubMed
van den, Hombergh J., Dalderop, E., and Smit, Y. Does iron therapy benefit children with severe malaria-associated anaemia? A clinical trial with 12 weeks supplementation of oral iron in young children from the Turiani Division, Tanzania. J.Trop.Pediatr. PubMed
Liabeuf S, Gras V, Moragny J, et al. Ulceration of the oral mucosa following direct contact with ferrous sulfate in elderly patients: a case report and a review of the French National Pharmacovigilance Database. Clin Interv Aging. 2014 Apr 25;9:737-40. PubMed
Qiao L, Feng Y. Intakes of heme iron and zinc and colorectal cancer incidence: a meta-analysis of prospective studies. Cancer Causes Control. 2013 Jun;24(6):1175-83. PubMed
Jalloh MA, Gregory PJ, Hein D, et al. Dietary supplement interactions with antiretrovirals: a systematic review. Int J STD AIDS. 2017 Jan;28(1):4-15. PubMed
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: Drug Interactions between Integrase Inhibitors and Other Drugs. AIDSinfo. July 14, 2016. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescen
Song I, Borland J, Arya N, Wynne B, Piscitelli S. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55(5):490-6. PubMed
Esan MO, Boele van Hensbroek M, Nkhoma E, et al. Iron supplementation in HIV infected Malawian children with anemia: a double-blind, randomized, controlled trial. Clin Inf Dis 2013;57(11):1626-34.doi:10.1093/cid/cit528. PubMed
Zlotkin S, Newton S, Aimone AM, et al. Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial. JAMA 2013;310(9):938-47. PubMed
Khambalia AZ, Aimone A, Nagubandi P, et al. High maternal iron status, dietary iron intake and iron supplement use in pregnancy and risk of gestational diabetes mellitus: a prospective study and systematic review. Diabet Med. 2016;33(9):1211-21. PubMed
Kinnunen TI, Luoto R, Helin A, Hemminki E. Supplemental iron intake and the risk of glucose intolerance in pregnancy: re-analysis of a randomised controlled trial in Finland. Matern Child Nutr. 2016;12(1):74-84.
Low MS, Speedy J, Styles CE, De-Regil LM, Pasricha SR. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev. 2016;4:CD009747. PubMed
Melit LE, Marginean CO, Mocanu S, Marginean MO. A rare case of iron-pill induced gastritis in a female teenager: A case report and a review of the literature. Medicine (Baltimore). 2017;96(30):e7550. PubMed
Neuberger A, Okebe J, Yahav D, Paul M. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev. 2016;2:CD006589. PubMed
Peña-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015;(10):CD009997. PubMed
Brabin B, Gies S, Roberts SA, et al. Excess risk of preterm birth with periconceptional iron supplementation in a malaria endemic area: analysis of secondary data on birth outcomes in a double blind randomized controlled safety trial in Burkina Faso. Mala PubMed
Kaundal R, Bhatia P, Jain A, et al. Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Ann Hematol 2020;99(1):57-63. PubMed
Li N, Zhao G, Wu W, et al. The efficacy and safety of vitamin C for iron supplementation in adult patients with iron deficiency anemia: A randomized clinical trial. JAMA Netw Open. 2020;3(11):e2023644. PubMed
Houston BL, Hurrie D, Graham J, et al. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open. 2018;8(4):e019240. PubMed
Koch RM, Tchernodrinski S, Principe DR. Case report: Rapid onset, ischemic-type gastritis after initiating oral iron supplementation. Front Med (Lausanne) 2022;9:1010897. PubMed
Milman NT. Iron supplementation in pregnant Danish women revisited: Effects on prepartum and postpartum iron deficiency, anemia, serum erythropoietin; including iron status, erythropoietin and anthropometrics in newborns. A randomized, placebo-controlled
Rogozinska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis. Lancet Haematol 2021;8(7):e503-e512. PubMed
Shah AA, Donovan K, Seeley C, et al. Risk of infection associated with administration of intravenous iron: A systematic review and meta-analysis. JAMA Netw Open 2021;4(11):e2133935. PubMed
Gamad N, Saha PK, Sharma P, Suri V, Chakrabarti A, Saha L. A randomized controlled trial comparing the efficacy, tolerability, and cost of oral iron preparations in iron-deficiency anemia in pregnancy. J Obstet Gynaecol Res 2021;47(11):3828-3841. PubMed
El-Hawy MA, Abd Al-Salam SA, Bahbah WA. Comparing oral iron bisglycinate chelate, lactoferrin, lactoferrin with iron and iron polymaltose complex in the treatment of children with iron deficiency anemia. Clin Nutr ESPEN 2021;46:367-371. PubMed
Adams A, Scheckel B, Habsaoui A, et al. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2 PubMed
Kancherla K, Constantin H, Kanawati A, Graham E. Iron-induced Hypophosphatemic Osteomalacia-An Atypical Case of Bilateral Femoral Stress Fractures. J Am Acad Orthop Surg Glob Res Rev 2023;7(5):e22. PubMed
Shi R, Marin JG, Beaulieu M. Skin staining following intravenous iron extravasation in a patient with chronic kidney disease: A case report. Can J Kidney Health Dis 2023;10:20543581231165705. PubMed
Varandas C, Vieira J, Correia CJ, et al. Hypersensitivity reactions to iron products: 10-year experience in a Portuguese tertiary Centre. Eur Ann Allergy Clin Immunol 2023.
Jara Vidal M, López García MC, Quílez Toboso RP. Kounis syndrome after intravenous iron administration. Med Clin (Barc) 2023. DOI
Jara Vidal M, Ruiz de Assín Valverde A, Aznar Rodríguez S. Severe hypophospathemia secondary to intravenous iron. Med Clin (Barc) 2023. DOI
Samões B, Silva B, Martins A, et al. Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report. Joint Bone Spine 2023;90(5):105586. PubMed
Seng NW, Barco JB, Wong MH, et al. Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series. Transfus Med 2023. PubMed
Fernandez-Flores A, Fernandez-Parrado M, Alzoghby-Abi Chaker J, Angulo AG. Axillary cutaneous hemosiderosis in a patient with hyperhidrosis, after intravenous iron infusion. Am J Dermatopathol 2023;45(7):463-465. PubMed
Ye S, Grill V, Luo J, Nguyen HH. Concurrent Denosumab and Parenteral Iron Therapy Precipitating Severe Hypocalcemia and Hypophosphatemia. JCEM Case Rep 2024;2(2):luae005. PubMed
Yerigeri K. Hemochromatosis in an Adult Female With Previous Iron Deficiency Anemia on Iron Supplementation. Cureus 2023;15(12):e50166. PubMed
Meyers M, Salmon M, Libert I, Klá&scaron;terský J. A meta-analysis on the risk of infection associated with intravenous iron therapy in cancer-associated anaemia: a double-edged sword?. Curr Opin Oncol 2024;36(4):223-232. PubMed
Short V, Allen R, Earley CJ, et al. A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia. Am J Hem PubMed
Bellos I, Frountzas M, Pergialiotis V. Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis. Transfus Med Rev 2020;34(3):188-194. PubMed
US Food and Drug Administration (FDA). Biktarvy Prescribing Information. October 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210251Orig1s020lbl.pdf. Accessed July 16, 2025.

See these in context on the Iron monograph →

Glycine 5 references

Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36.. PubMed
Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999;156:145-7.. PubMed
Gusev EI, Skvortsova VI, Dambinova SA, et al. Neuroprotective effects of glycine for therapy of acute ischaemic stroke. Cerebrovasc Dis 2000;10:49-60. PubMed
Inagawa K, Kawai N, Ono K, Sukegawa E, Tsubuku S, Takahashi M. Assessment of acute adverse effects of glycine ingestion at a high dose in human volunteers. Seikatsu Eisei. 2006; 50:27-32.
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol. 2013 Aug;23(8):931-40. PubMed

See these in context on the Glycine monograph →

Aspartic Acid 1 reference

Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: The National Academies Press, 2005. Available at: https://doi.org/10.17226 DOI

See these in context on the Aspartic Acid monograph →

L-tryptophan 18 references

Messiha FS. Fluoxetine: adverse effects and drug-drug interactions. J Toxicol Clin Toxicol 1993;31:603-30. PubMed
Devoe LD, Castillo RA, Searle NS. Maternal dietary substrates and human fetal biophysical activity. The effects of tryptophan and glucose on fetal breathing movements. Am J Obstet Gynecol 1986;155:135-9. DOI
Lieberman HR, Corkin S, Spring BJ. The effects of dietary neurotransmitter precursors on human behavior. Am J Clin Nutr 1985;42:366-70. PubMed
U. S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements. Information Paper on L-Tryptophan and 5-hydroxy-L-tryptophan, February 2001.
Sullivan EA, Kamb ML, Jones JL, et al. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina. Arch Intern Med 1996;156:973-9. DOI
Philen RM, Hill RH, Flanders WD, et al. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. Am J Epidemiol 1993;138:154-9. PubMed
Bohme A, Wolter M, Hoelzer D. L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia. Ann Hematol 1998;77:235-8. PubMed
Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3. PubMed
Priori R, Conti F, Luan FL, et al. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents. Eur J Pediatr 1994;153:344-6..
Klein R, Berg PA. A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome. Clin Investig 1994;72:541-9.. PubMed
Simat TJ, Kleeberg KK, Muller B, Sierts A. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 1999;467:469-80.. PubMed
Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002;(1):CD003198. PubMed
Kilbourne EM, Philen RM, Kamb ML, Falk H. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. J Rheumatol Suppl 1996;46:81-8.
Horwitz RI, Daniels SR. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome. J Rheumatol Suppl 1996;46:60-72.
Shapiro S. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique. J Rheumatol Suppl 1996;46:44-58.
Mayeno AN, Gleich GJ. The eosinophilia-myalgia syndrome: lessons from Germany. Mayo Clin Proc 1994;69:702-4. PubMed
Carr L, Ruther E, Berg PA, Lehnert H. Eosinophilia-myalgia syndrome in Germany: an epidemiologic review. Mayo Clin Proc 1994;69:620-5. PubMed
Ullrich SS, Fitzgerald PCE, Giesbertz P, Steinert RE, Horowitz M, Feinle-Bisset C. Effects of intragastric administration of tryptophan on the blood glucose response to a nutrient drink and energy intake, in lean and obese men. Nutrients 2018;10(4). pii: PubMed

See these in context on the L-tryptophan monograph →

Vitamin D 26 references

McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Tatro DS, ed. Drug Interactions Facts. Facts and Comparisons Inc., St. Louis, MO. 1999.
Koutkia P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001;345:66-7. PubMed
Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking AI(OH)3. Clin Nephrol 1986;26:146-9.
Crowe M, Wollner L, Griffiths RA. Hypercalcemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3.
Parfitt AM. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. Ann Intern Med 1972;77:557-63. PubMed
Thiazide diuretics and the risk of osteoporosis. Pharmacist's Letter/Prescriber's Letter 2003;19(11):191105.
Moon J. The role of vitamin D in toxic metal absorption. J Am Coll Nutr 1994;13:559-64.
Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1alphaOH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol 1989;31:123-7.
Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol 1985;249:G209-13. PubMed
Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. PubMed
Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
Cox KA, Dunn MA. Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. J Nutr 2001;131:2007-13. PubMed
Escribano, J., Balaguer, A., Pagone, F., Feliu, A., and Roque, I. Figuls. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane.Database.Syst.Rev. 2009;(1):CD004754. PubMed
Carlton, S., Clopton, D., and Cappuzzo, K. A. Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity. Consult Pharm 2010;25(3):171-177. PubMed
Wang, H., Xia, N., Yang, Y., and Peng, D. Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2012;11:42. PubMed
Turner AN, Carr Reese P, Fields KS, Anderson J, Ervin M, Davis JA, Fichorova RN, Roberts MW, Klebanoff MA, Jackson RD. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet G PubMed
Weiner M, Epstein FH. Signs and symptoms of electrolyte disorders. Yale J Biol Med. 1970;43(2):76-109.
Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. BMJ. 2017;359:j5237. PubMed
Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial. JAMA. 2021.
Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol 2013;136:54-8. PubMed
Doyle D, Browne U, Brickley A, Murphy D. Vitamin D-induced hypercalcaemia and acute kidney injury in sarcoidosis. BMJ Case Rep 2023;16(1):e250580. PubMed
Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database Syst Rev 2023;2(2):CD011511. PubMed
Kinesya E, Santoso D, Gde Arya N, et al. Vitamin D as adjuvant therapy for diabetic foot ulcers: Systematic review and meta-analysis approach. Clin Nutr ESPEN 2023;54:137-143. PubMed

See these in context on the Vitamin D monograph →

Methionine 12 references

La Vecchia C, Negri E, Franceschi S, Decarli A. Case-control study on influence of methionine, nitrite, and salt on gastric carcinogenesis in northern Italy. Nutr Cancer 1997;27:65-8. PubMed
Btaiche IF, Khalidi N. Parenteral nutrition-associated liver complications in children. Pharmacotherapy 2002;22:188-211.. PubMed
Cottington EM, LaMantia C, Stabler SP, et al. Adverse event associated with methionine loading test: a case report. Arterioscler Thromb Vasc Biol 2002;22:1046-50.. PubMed
Anon. Should methionine be added to paracetamol formulations? Drug Ther Perspect 1997;10:11-3. DOI
Smulders, Y. M., Rakic, M., Slaats, E. H., Treskes, M., Sijbrands, E. J., Odekerken, D. A., Stehouwer, C. D., and Silberbusch, J. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and c
McAuley, D. F., Hanratty, C. G., McGurk, C., Nugent, A. G., and Johnston, G. D. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation. J.Toxicol.Clin.Toxicol. 1999;37(4):435-440. PubMed
Hanratty, C. G., McGrath, L. T., McAuley, D. F., Young, I. S., and Johnston, G. D. The effects of oral methionine and homocysteine on endothelial function. Heart 2001;85(3):326-330. PubMed
Ward, M., McNulty, H., McPartlin, J., Strain, J. J., Weir, D. G., and Scott, J. M. Effect of supplemental methionine on plasma homocysteine concentrations in healthy men: a preliminary study. Int.J.Vitam.Nutr.Res. 2001;71(1):82-86. PubMed
Yaghmai, R., Kashani, A. H., Geraghty, M. T., Okoh, J., Pomper, M., Tangerman, A., Wagner, C., Stabler, S. P., Allen, R. H., Mudd, S. H., and Braverman, N. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient
Talukdar R, Murthy HV, Reddy DN. Role of methionine containing antioxidant combination in the management of pain in chronic pancreatitis: a systematic review and meta-analysis. Pancreatology 2015;15(2):136-44. PubMed
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: The National Academies Press, 2005. Available at: https://doi.org/10.17226 DOI
Khairan P, Sobue T, Eshak ES, et al. Association of B Vitamins and Methionine Intake with the Risk of Gastric Cancer: The Japan Public Health Center-based Prospective Study. Cancer Prev Res (Phila) 2022;15(2):101-110. PubMed

See these in context on the Methionine monograph →

Serine 3 references

Fridman V, Suriyanarayanan S, Novak P, et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology. 2019;92(4):e359-e370.
Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010 Aug;121(1-3):125-30. PubMed
Levine TD, Miller RG, Bradley WG, et al. Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1-2):107-111. PubMed

See these in context on the Serine monograph →

Tyrosine 4 references

Meyer JS, Welch KM, Deshmukh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease. J Amer Geriat Soc 1977;25:289-98.
DiPiro JT, Talbert RL, Yee GC, et al; eds. Pharmacotherapy: A pathophysiologic approach. 4th ed. Stamford, CT: Appleton & Lange, 1999.
Wood DR, Reimherr FW, Wender PH. Amino acid precursors for the treatment of attention deficit disorder, residual type. Psychopharmacol Bull 1985;21:146-9.
van Spronsen FJ, van Rijn M, Bekhof J. Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets. Am J Clin Nutr 2001;73:153-7. PubMed

See these in context on the Tyrosine monograph →

Histidine 3 references

Histidine — MedlinePlus (U.S. National Library of Medicine) Source
Amino Acids — MedlinePlus (U.S. National Library of Medicine) Source
Dietary Supplements: What You Need to Know — NIH Office of Dietary Supplements Source

See these in context on the Histidine monograph →

Lysine 7 references

Thein DJ, Hurt WC. Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis. Oral Surg Oral Med Oral Pathol 1984;58:659-66. PubMed
McCune MA, Perry HO, Muller SA, O'Fallon WM. Treatment of recurrent herpes simplex infections with L-lysine monohydrochloride. Cutis 1984;34:366-73.
DiGiovanna JJ, Blank H. Failure of lysine in frequently recurrent herpes simplex infection. Treatment and prophylaxis. Arch Dermatol 1984;120:48-51. DOI
Milman N, Scheibel J, Jessen O. Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study. Acta Derm Venereol 1980;60:85-7.
Griffith RS, Walsh DE, Myrmel KH, et al. Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. Dermatologica 1987;175:183-90. DOI
Lo JC, Chertow GM, Rennke H, Seifter JL. Fanconi's syndrome and tubulointerstitial nephritis in association with L-lysine ingestion. Am J Kidney Dis 1996;28:614-7. PubMed
Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15370-5.

See these in context on the Lysine monograph →

Phenylalanine 23 references

Rouse B, Azen C, Koch R, et al. Maternal phenylketonuria collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. Am J Med Genet 1997;69:89-95. DOI
Sturtevant FM. Use of aspartame in pregnancy. Int J Fertil 1985;30:85-7.
Silkaitis RP, Mosnaim AD. Pathways linking L-phenylalanine and 2-phenylethylamine with p-tyramine in rabbit brain. Brain Res 1976;114:105-15.
Lehmann WD, Theobald N, Fischer R, Heinrich HC. Stereospecificity of phenylalanine plasma kinetics and hydroxylation in man following oral application of a stable isotope-labelled pseudo-racemic mixture of L- and D-phenylalanine. Clin Chim Acta 1983;128 PubMed
Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology 1997;16:136-46. PubMed
Siddiqui AH, Stolk LM, Bhaggoe R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology 1994;88:215-8. PubMed
Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 1984;59:81-7. PubMed
Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8. PubMed
Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-37. PubMed
Juncos JL, Fabbrini G, Mouradian MM, et al. Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987;44:1003-5. PubMed
Eriksson T, Granerus AK, Linde A, et al. "On-off" phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38:1245-8. PubMed
Baker GB, Bornstein RA, Rouget AC, et al. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol Psychiatry 1991;29:15-22.. PubMed
Wood DR, Reimherr FW, Wender PH. Treatment of attention deficit disorder with DL-phenylalanine. Psychiatry Res 1985;16:21-6.. PubMed
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, DC: National Academy Press, 2002. Available at: http://www.n
Cederbaum S. Phenylketonuria: an update. Curr Opin Pediatr 2002;14:702-6. PubMed
Cejudo-Ferragud, E., Nacher, A., Polache, A., Cercos-Fortea, T., Merino, M., and Casabo, V. G. Evidence of competitive inhibition for the intestinal absorption of baclofen by phenylalanine. Int J of Pharm (Amsterdam) 1996;132:63-69. DOI
Fischer, E., Heller, B., Nachon, M., and Spatz, H. Therapy of depression by phenylalanine. Preliminary note. Arzneimittelforschung. 1975;25(1):132.
Beckmann, H., Strauss, M. A., and Ludolph, E. Dl-phenylalanine in depressed patients: an open study. J.Neural Transm. 1977;41(2-3):123-134. PubMed
Sabelli, H. C., Fawcett, J., Gusovsky, F., Javaid, J. I., Wynn, P., Edwards, J., Jeffriess, H., and Kravitz, H. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplem
Cotzias, G. C., Van Woert, M. H., and Schiffer, L. M. Aromatic amino acids and modification of parkinsonism. N Engl.J Med 2-16-1967;276(7):374-379. PubMed
Kravitz, H. M., Sabelli, H. C., and Fawcett, J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. J Am Osteopath.Assoc 1984;84(1 Suppl):119-123. DOI
Mann, J., Peselow, E. D., Snyderman, S., and Gershon, S. D-phenylalanine in endogenous depression. Am.J.Psychiatry 1980;137(12):1611-1612. PubMed
Katoulis AC, Alevizou A, Bozi E, et al. A randomized, double-blind, vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines. Clin Exp Dermatol 2010;35(5):473-6. PubMed

See these in context on the Phenylalanine monograph →

Threonine 4 references

Tandan R, Bromberg MB, Forshew D, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology 1996;47:1220-6. PubMed
Lee A, Patterson V. A double blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993;88:334-8. PubMed
Blin O, Pouget J, Aubrespy G, et al. A double-blind placebo controlled trial of L-threonine in amyotrophic lateral sclerosis. J Neurol 1992;239:79-81.
Roufs JB. L-threonine as a symptomatic treatment for amyotrophic lateral sclerosis (ALS). Med Hypotheses 1991;34:20-3. PubMed

See these in context on the Threonine monograph →

Proline 4 references

Jennings A, MacGregor A, Spector T, Cassidy A. Amino acid intakes are associated with bone mineral density and prevalence of low bone mass in women: Evidence from discordant monozygotic twins. J Bone Miner Res. 2016;31(2):326-35. PubMed
Gracia-Marco L, Bel-Serrat S, Cuenca-Garcia M, et al. Amino acids intake and physical fitness among adolescents. Amino Acids. 2017;49(6):1041-1052. PubMed
Jamdar J, Rao B, Netke S, et al. Reduction in tibial shaft fracture healing time with essential nutrient supplementation containing ascorbic acid, lysine, and proline. J Altern Complement Med. 2004;10(6):915-6.
Mehl AA, Damião AO, Viana SD, Andretta CP. Hard-to-heal wounds: a randomised trial of an oral proline-containing supplement to aid repair. J Wound Care 2021;30(1):26-31. PubMed

See these in context on the Proline monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

Keep exploring

Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team

All Plant Protein Powder Ingredients & Drug Interactions

Check Your Meds Against All Plant Protein Powder by Nutrilite

HelloPharmacist Scorecard of All Plant Protein Powder by Nutrilite

What’s inside

Does it work?

How safe is it?

Meds to double-check

The bottom line

General information

Supplement Facts

Supplement Facts

All Plant Protein Powder by Nutrilite label

The Ingredients in All Plant Protein Powder by Nutrilite

Protein

Sodium

Potassium

Calcium

Iron

Vitamin D

One serving provides the following Typical Amino Acids

All Plant Protein Powder by Nutrilite Drug Interactions

HelloPharmacist Interaction Report

Want to check YOUR meds against All Plant Protein Powder?

Ingredients driving the most interactions

Individual Drug Interactions

Each ingredient & the kinds of drugs it affects

Vitamin D8 drug types · 715 drugs

Tryptophan2 drug types · 394 drugs

Sodium7 drug types · 205 drugs

Calcium18 drug types · 168 drugs

Iron13 drug types · 80 drugs

Potassium3 drug types · 62 drugs

Tyrosine2 drug types · 21 drugs

Phenylalanine3 drug types · 16 drugs

Threonine1 drug type · 3 drugs

Glycine1 drug type · 1 drug

Lysine1 drug type · 1 drug

Brand information

More from Nutrilite

Other products with these ingredients

All Plant Protein Powder by Nutrilite: Common Questions

Not sure if All Plant Protein Powder is safe with your meds?

The Full Monographs Behind All Plant Protein Powder’s Ingredients

Sodium

Potassium

Calcium

Iron

Vitamin D

Glycine

Aspartic Acid

L-tryptophan

Methionine

Serine

Tyrosine

Histidine

Lysine

Phenylalanine

Threonine

Proline

Sources & How We Checked

The 294 references behind this product’s interaction data